Vedolizumab-induced cholestatic liver injury
Gastroenterol Hepatol. 2022 Jan;45(1):64-65.
doi: 10.1016/j.gastrohep.2020.11.009.
Epub 2020 Nov 25.
[Article in
English,
Spanish]
Affiliations
- 1 Department of Digestive Diseases, Valme University Hospital, UGC Digestive Diseases, Servicio Andaluz de Salud, Seville E-41014, Spain. Electronic address: mrojasferia@gmail.com.
- 2 Department of Internal Medicine, Valme University Hospital, UGC Internal Medicine, Servicio Andaluz de Salud, Seville E-41014, Spain.
- 3 Department of Digestive Diseases, Valme University Hospital, UGC Digestive Diseases, Servicio Andaluz de Salud, Seville E-41014, Spain.
No abstract available
MeSH terms
-
Aged, 80 and over
-
Anti-Inflammatory Agents / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Chemical and Drug Induced Liver Injury / diagnosis
-
Chemical and Drug Induced Liver Injury / drug therapy
-
Chemical and Drug Induced Liver Injury / etiology*
-
Cholestasis, Intrahepatic / chemically induced*
-
Cholestasis, Intrahepatic / diagnosis
-
Cholestasis, Intrahepatic / drug therapy
-
Colitis, Ulcerative / drug therapy*
-
Gastrointestinal Agents / administration & dosage
-
Gastrointestinal Agents / adverse effects*
-
Humans
-
Maintenance Chemotherapy
-
Male
-
Prednisone / administration & dosage
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal, Humanized
-
Gastrointestinal Agents
-
vedolizumab
-
Prednisone